

# Elena Gershtein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3986191/publications.pdf>

Version: 2024-02-01

68  
papers

568  
citations

687363

13  
h-index

752698

20  
g-index

72  
all docs

72  
docs citations

72  
times ranked

762  
citing authors

#	ARTICLE	IF	CITATIONS
1	Soluble forms of PD-1/PD-L immune checkpoint receptor and ligand in blood serum of breast cancer patients: association with clinical pathologic factors and molecular type of the tumor. <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2022, 67, 76-80.	0.5	0
2	Clinical implication of kidney injury molecule (KIM-1) in blood plasma of renal-cell cancer patients. <i>Onkourologiya</i> , 2021, 16, 39-47.	0.3	3
3	Prognostic significance of soluble forms of immune checkpoint PD-1/PDL1 receptor and ligand in blood plasma of gastric cancer patients. <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2021, 66, 139-146.	0.5	4
4	Immunosuppression Factors PD-1, PD-L1, and IDO1 and Colorectal Cancer. <i>Doklady Biochemistry and Biophysics</i> , 2021, 497, 66-70.	0.9	5
5	Vascular Endothelial Growth Factor and Soluble Forms of Its Receptors 1 and 2 in Gastric Cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2021, 170, 791-794.	0.8	2
6	Prognostic significance of the TNM system criteria, levels of serum insulin-like growth factors and their transport proteins, VEGF and MMP-7 in colorectal cancer. <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2021, 66, 459-464.	0.5	1
7	Clinical and prognostic significance of the soluble form of the VISTA immunity control point in patients with primary bone tumors. <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2021, 66, 533-538.	0.5	1
8	Prognostic significance of VEGF signaling system components and matrix metalloproteinases in blood serum of gastric cancer patients. <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2021, 66, 650-654.	0.5	1
9	Key Immune Checkpoint PD-1/PD-L1 Signaling Pathway Components in the Blood Serum from Patients with Bone Tumors. <i>Bulletin of Experimental Biology and Medicine</i> , 2020, 170, 64-68.	0.8	7
10	Comparative Analysis of MMP-8 and MMP-9 Concentrations in Crevicular and Peri-Implants Sulcular Fluids. <i>Bulletin of Experimental Biology and Medicine</i> , 2020, 170, 19-23.	0.8	2
11	Prognostic Role of Matrix Metalloproteinases 2, 7, 8, 9 and Their Type 1 Tissue Inhibitor in Blood Serum of Patients with Kidney Cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2020, 168, 673-676.	0.8	4
12	Comparative analysis of the levels of soluble forms of receptor and ligand of the immunity control point PD-1 / PD-L1 in the blood serum of patients with typical bone osteosarcoma and chondrosarcoma. <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2020, 65, 669-675.	0.5	3
13	Key VEGF signaling system components and matrix metalloproteinases in the diagnosis and prognosis of overall survival of patients with renal cell cancer. <i>Al'manah Klinicheskoy Mediciny</i> , 2020, 48, 78-83.	0.3	0
14	Novel miRNAs as Potential Regulators of PD-1/PD-L1 Immune Checkpoint, and Prognostic Value of MIR9-1 and MIR124-2 Methylation in Ovarian Cancer. <i>Molecular Biology</i> , 2020, 54, 870-875.	1.3	1
15	Kidney Injury Molecule-1 (KIM-1) in Blood Plasma of Patients with Clear-Cell Carcinoma. <i>Bulletin of Experimental Biology and Medicine</i> , 2019, 167, 388-392.	0.8	11
16	Comparative Analysis of Blood Plasma Proteome in Patients with Renal Cell Carcinoma. <i>Bulletin of Experimental Biology and Medicine</i> , 2019, 167, 91-96.	0.8	4
17	Soluble Ligand of the Immune Checkpoint Receptor (sPD-L1) in Blood Serum of Patients with Renal Cell Carcinoma. <i>Bulletin of Experimental Biology and Medicine</i> , 2019, 166, 353-357.	0.8	20
18	Clinical Significance of Matrix Metalloproteinases in Blood Plasma of Patients with Gastric Cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2019, 166, 373-376.	0.8	9

#	ARTICLE	IF	CITATIONS
19	Soluble forms of the immune check-point receptor PD-1 and its ligand PD-L1 in blood serum of patients with renal cell carcinoma: clinical and pathologic correlations. <i>Onkourologiya</i> , 2019, 15, 15-22.	0.3	8
20	CLINICAL AND LABORATORY EVALUATION OF THE EFFECTIVENESS OF THE APPLICATION OF NONSTEROID ANTI-INFLAMMATORY PREPARATION OF THE COXIB GROUP. <i>Archiv Euromedica</i> , 2019, 9, 160-164.	0.2	1
21	Matrix Metalloproteinases and Their Tissue Inhibitors in Blood Serum of Patients with Endometrial Cancer: Clinical and Morphological Correlations. <i>Bulletin of Experimental Biology and Medicine</i> , 2018, 165, 75-79.	0.8	6
22	Modern approaches to kidney cancer immunotherapy. <i>Onkourologiya</i> , 2018, 14, 54-67.	0.3	15
23	CLINICAL CHARACTERISTICS OF MATRIX METALLOPROTEINASES 2, 7, 9 AND THEIR TISSUE INHIBITORS 1 AND 2 TYPE IN THE BLOOD SERUM OF PATIENTS WITH CANCER ENDOMETRY. <i>Problems of Biological Medical and Pharmaceutical Chemistry</i> , 2018, 21, .	0.2	0
24	Receptor Activator of Nuclear Transcription Factor NF- $\kappa$ B (RANK), Its Ligand RANKL, and Natural Inhibitor of RANKL Osteoprotegerin (OPG) in the Blood Serum of Patients with Primary Bone Tumors. <i>Bulletin of Experimental Biology and Medicine</i> , 2017, 163, 478-481.	0.8	9
25	Association between the Prevalence of Somatic Mutations in PIK3CA Gene in Tumors and Clinical and Morphological Characteristics of Breast Cancer Patients. <i>Bulletin of Experimental Biology and Medicine</i> , 2017, 163, 250-254.	0.8	7
26	Insulin-Like Growth Factors (IGF) and IGF-Binding Proteins (IGFBP) in the Serum of Patients with Ovarian Tumors. <i>Bulletin of Experimental Biology and Medicine</i> , 2016, 160, 814-816.	0.8	15
27	Regulatory Proteins of Epithelial-Mesenchymal Transition and Some Components of VEGF Signaling Pathway in Breast Cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2016, 160, 802-806.	0.8	3
28	Clinical prospects of IGF-signaling system components study in ovarian cancer patients. <i>Drug Metabolism and Personalized Therapy</i> , 2015, 30, 75-85.	0.6	3
29	Insulin-Like Growth Factors (IGF), IGF-Binding Proteins (IGFBP), and Vascular Endothelial Growth Factor (VEGF) in Blood Serum of Patients with Colorectal Cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2014, 156, 684-688.	0.8	22
30	Prognostic Role of Tumor-Associated Proteases in Colorectal Cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2013, 154, 365-369.	0.8	8
31	CLINICAL PROSPECTS OF TUMOR-ASSOCIATED PROTEASES AND THEIR TISSUE INHIBITORS INVESTIGATION IN ONCOLOGIC PATIENTS. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2013, 68, 16-27.	0.6	12
32	Matrix Metalloproteinases and Inflammatory Cytokines in Oral Fluid of Patients with Chronic Generalized Periodontitis and Various Construction Materials. <i>Bulletin of Experimental Biology and Medicine</i> , 2012, 153, 72-76.	0.8	10
33	Vascular Endothelial Growth Factor and Type 2 Receptor for This Factor in Vascular Malformations. <i>Bulletin of Experimental Biology and Medicine</i> , 2011, 150, 481-484.	0.8	8
34	Matrix Metalloproteinases 2, 7, and 9 in Tumors and Sera of Patients with Breast Cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2011, 151, 359-362.	0.8	18
35	Relationship between the Expression of VEGF Signal Components and Matrix Metalloproteinases in Ovarian Tumors. <i>Bulletin of Experimental Biology and Medicine</i> , 2011, 151, 449-453.	0.8	4
36	Content of Matrix Metalloproteinase-8 and Matrix Metalloproteinase-9 in Oral Fluid of Patients with Chronic Generalized Periodontitis. <i>Bulletin of Experimental Biology and Medicine</i> , 2011, 152, 240-244.	0.8	15

#	ARTICLE	IF	CITATIONS
37	Matrix Metalloproteinases 2, 7, 9 and Tissue Inhibitor of Matrix Metalloproteinase-1 in the Sera of Patients with Bone Tumors. Bulletin of Experimental Biology and Medicine, 2010, 149, 233-235.	0.8	16
38	Urokinase and Tissue Plasminogen Activators and Their PAI-1 Inhibitor in Tumors of Patients with Oral Mucosal Cancer: Relationship with the Main Clinical Morphological Factors. Bulletin of Experimental Biology and Medicine, 2010, 149, 347-350.	0.8	3
39	Vascular Endothelial Growth Factor and Its Type 2 Receptor in Hepatocellular Carcinoma. Bulletin of Experimental Biology and Medicine, 2010, 149, 749-752.	0.8	15
40	The Expression and DNA-Binding Activity of NF- $\kappa$ B Nuclear Transcription Factor in the Tumors of Patients with Breast Cancer. Bulletin of Experimental Biology and Medicine, 2010, 150, 71-74.	0.8	7
41	Matrix Metalloproteinases 2, 7, and 9 and Tissue Inhibitor of Metalloproteinases-1 in Tumors and Serum of Patients with Ovarian Neoplasms. Bulletin of Experimental Biology and Medicine, 2010, 149, 628-631.	0.8	17
42	Molecular Markers of Tumors. Bulletin of Experimental Biology and Medicine, 2009, 148, 230-237.	0.8	0
43	Expression of VEGF and VEGFR2 in tumors during neoadjuvant therapy of patients with breast cancer. Bulletin of Experimental Biology and Medicine, 2008, 145, 245-248.	0.8	7
44	Matrix metalloproteinases 2, 3, 13 and their type 2 tissue inhibitor in tumors and plasma of patients with colorectal cancer. Bulletin of Experimental Biology and Medicine, 2008, 145, 362-366.	0.8	9
45	Vascular endothelial growth factor and its type 2 receptor in tumors and serum of patients with renal cancer. Bulletin of Experimental Biology and Medicine, 2008, 145, 744-747.	0.8	5
46	Soluble fragment of Her2/neu receptor in the serum of patients with breast cancer with different levels of this protein expression in the tumor. Bulletin of Experimental Biology and Medicine, 2007, 143, 449-451.	0.8	4
47	Matrix metalloproteinases 7 and 9 and their types 1 and 4 tissue inhibitors in tumors and plasma of patients with colorectal cancer. Bulletin of Experimental Biology and Medicine, 2007, 143, 459-462.	0.8	10
48	Activation of mitogenic pathways and sensitization to estrogen-induced apoptosis: two independent characteristics of tamoxifen-resistant breast cancer cells?. Breast Cancer Research and Treatment, 2006, 100, 1-11.	2.5	112
49	Sensitization of MCF-7 breast cancer cells to the apoptotic effect of estradiol. Bulletin of Experimental Biology and Medicine, 2006, 141, 357-360.	0.8	3
50	Activated Protein kinase B in Breast Cancer. Bulletin of Experimental Biology and Medicine, 2005, 139, 608-610.	0.8	4
51	Role of Phosphatidylinositol-3 Kinase in Regulation of Differential Sensitivity of Melanoma Cells to Antitumor Agents. A Model for Hormone Resistance Development in Tumor Cells. Biochemistry (Moscow), 2004, 69, 322-330.	1.5	4
52	Vascular endothelial growth factor in tumor tissue and blood serum from patients with breast cancer. Bulletin of Experimental Biology and Medicine, 2003, 135, 85-88.	0.8	5
53	Title is missing!. Molecular Biology, 2003, 37, 585-590.	1.3	4
54	Role of vascular endothelial growth factor during breast cancer. Bulletin of Experimental Biology and Medicine, 2002, 133, 521-528.	0.8	14

#	ARTICLE	IF	CITATIONS
55	Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors. Bulletin of Experimental Biology and Medicine, 2001, 131, 67-72.	0.8	11
56	Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms. Bulletin of Experimental Biology and Medicine, 2001, 132, 670-674.	0.8	6
57	Plasminogen activators and their inhibitor in bone tumors and tumor-like damages. Bulletin of Experimental Biology and Medicine, 2001, 132, 780-782.	0.8	6
58	Expression of phosphatidylinositol-3 kinase in lung cancer. Bulletin of Experimental Biology and Medicine, 2000, 130, 1166-1168.	0.8	3
59	Epidermal growth factor receptors in endometrial adenomatosis. Bulletin of Experimental Biology and Medicine, 1999, 127, 40-43.	0.8	1
60	Dependence of antitumor effect of hormonal cytostatic cortifen on expression of glucocorticoid receptors in brain tumor cells. Bulletin of Experimental Biology and Medicine, 1999, 127, 299-300.	0.8	1
61	Clinical and prognostic importance of expression of epidermal growth factor receptors in non-small-cell lung carcinoma. Bulletin of Experimental Biology and Medicine, 1999, 127, 404-407.	0.8	2
62	The role of phosphatidylinositol 3-kinase in the regulation of cell response to steroid hormones. Biochimica Et Biophysica Acta - Molecular Cell Research, 1999, 1450, 434-443.	4.1	14
63	Phosphatidylinositol 3-kinase expression in human breast cancer. Clinica Chimica Acta, 1999, 287, 59-67.	1.1	30
64	Receptors for the epidermal growth factor and estrogens in primary bone tumors. Bulletin of Experimental Biology and Medicine, 1996, 122, 720-723.	0.8	0
65	Comparative analysis of the sensitivity of endometrial cancer cells to epidermal growth factor and steroid hormones. Cancer, 1995, 76, 2524-2529.	4.1	6
66	Action of tamoxifen on the reproductive organs of guinea pigs. Bulletin of Experimental Biology and Medicine, 1982, 94, 1713-1715.	0.8	0
67	Changes in relations between two pathways of synthesis of RNA precursors in the tissues of animals with fast growing hepatomas. Bulletin of Experimental Biology and Medicine, 1979, 87, 264-266.	0.8	1
68	RECEPTOR ACTIVATOR OF NUCLEAR TRANSCRIPTION FACTOR NF- $\kappa$ B (RANK), ITS LIGAND (RANKL) AND NATURAL INHIBITOR OSTEOPROTEGERIN (OPG) IN BLOOD SERUM OF PRIMARY BONE TUMOR PATIENTS: ASSOCIATION WITH CLINICOPATHOLOGICAL FEATURES AND INFLAMMATORY CYTOKINES LEVELS. , 0, , .		0